Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Determination of Pyridostigmine Bromide in Presence of its Related Impurities by Four Modified Classical Least Square Based Models: A Comparative Study

Author(s): Ibrahim A. Naguib, Fatma F. Abdallah*, Aml A. Emam and Eglal A. Abdelaleem

Volume 17, Issue 1, 2021

Published on: 15 July, 2019

Page: [87 - 94] Pages: 8

DOI: 10.2174/1573412915666190715094347

Price: $65

Abstract

Introduction: Novel manipulations of the well-known classical least squares multivariate calibration model were explained in detail as a comparative analytical study in this research work. In addition to the application of plain classical least squares model, two preprocessing steps were tried, where prior to modeling with classical least squares, first derivatization and orthogonal projection to latent structures were applied to produce two novel manipulations of the classical least square-based model. Moreover, spectral residual augmented classical least squares model is included in the present comparative study.

Quantitative determination of pyridostigmine bromide in the presence of its two related substances; impurity A and impurity B was considered as a case study to construct the comparison.

Method: 3 factor 4 level design was implemented constructing a training set of 16 mixtures with different concentrations of the studied components. To investigate the predictive ability of the studied models; a test set consisting of 9 mixtures was constructed.

Results: The key performance indicator of this comparative study was the root mean square error of prediction for the independent test set mixtures, where it was found 1.367 when classical least squares applied with no preprocessing method, 1.352 when first derivative data was implemented, 0.2100 when orthogonal projection to latent structures preprocessing method was applied and 0.2747 when spectral residual augmented classical least squares was performed.

Conclusion: Coupling of classical least squares model with orthogonal projection to latent structures preprocessing method produced significant improvement of the predictive ability of it.

Keywords: First derivative, Orthogonal projection to latent structures, Classical least squre, Spectral residual augmented classical least squares, Pyridostigmine bromide.

« Previous
Graphical Abstract

[1]
Siddiqui MR, AlOthman ZA. = Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab J Chem 2017; 10: S1409-21.
[http://dx.doi.org/10.1016/j.arabjc.2013.04.016]
[2]
Alothman ZA, Rahman N, Siddiqui MR. Review on pharmaceutical impurities, stability studies and degradation products: an analytical approach. Reviews in Advanced Sciences and Engineering 2013; 2(2): 155-66.
[http://dx.doi.org/10.1166/rase.2013.1039]
[3]
Rahman N, Azmi SNH, Wu HF. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accredit Qual Assur 2006; 11(1-2): 69-74.
[http://dx.doi.org/10.1007/s00769-006-0095-y]
[4]
Q2 (R1) Validation of Aanalytical Procedures. Proceedings of the International Conference on Harmonization. Geneva. 2005.
[5]
Lotfy HM, Saleh SS. Recent De-velopment in ultraviolet spectrophotome-try through the last decade (2006–2016): a review. Int J Pharm Pharm Sci 2016; 8(10): 40-56.
[http://dx.doi.org/10.22159/ijpps.2016v8i10.13537]
[6]
The British Pharmacopoeia”, Her Majesty. The Stationary Office london 2013.
[7]
The United States Pharmacopeia, 34 Ed., National Formulary 29,United States Pharmacopeia convention INC, USA. 2011.
[8]
Merck Index. 13th ed. Merck Research Laboratories Division of MERCK & CO., Inc: Whitehouse Station, NJ, USA 2001.
[9]
Martindale- Extra Pharmacopoeia 34th Ed., "The Complete Drug References"; The pharmaceutical Press: London, UK 2005.
[10]
Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther 1985; 37(5): 495-501.
[http://dx.doi.org/10.1038/clpt.1985.78] [PMID: 3987173]
[11]
Sapolsky RM. The stress of Gulf War syndrome. Nature 1998; 393(6683): 308-9.
[http://dx.doi.org/10.1038/30606] [PMID: 9620793]
[12]
Xu M, Tan Q. Content determination of pyridostigmine bromide in tablets by UV spectrophotometry. J .Zhangguo yaofang 2011; 22: 743-5.
[13]
Yakatan GJ, Tien J-Y. Quantitation of pyridostigmine in plasma using high-performance liquid chromatography. J Chromatogr A 1979; 164(3): 399-403.
[http://dx.doi.org/10.1016/S0378-4347(00)81242-6] [PMID: 544615]
[14]
Blick DW, Murphy MR, Brown GC, Yochmowitz MG, Fanton JW, Hartgraves SL. Acute behavioral toxicity of pyridostigmine or soman in primates. Toxicol Appl Pharmacol 1994; 126(2): 311-8.
[http://dx.doi.org/10.1006/taap.1994.1121] [PMID: 8209384]
[15]
Needham SR, Ye B, Smith JR, Korte WD. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of pyridostigmine bromide from guinea pig plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 796(2): 347-54.
[http://dx.doi.org/10.1016/j.jchromb.2003.08.021] [PMID: 14581074]
[16]
Cherstniakova S, Garcia G, Strong J, et al. Simultaneous determination of N, N-diethyl-M-toluamide and permethrin by GC-MS and pyridostigmine bromide by HPLC in human plasma. Application to pharmacokinetic studies. Clin Pharmacol Ther 2003; 73(2): 27.
[http://dx.doi.org/10.1016/S0009-9236(03)90453-X]
[17]
Chan K, Williams NE, Baty JD, Calvey TN. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J Chromatogr A 1976; 120(2): 349-58.
[http://dx.doi.org/10.1016/S0021-9673(76)80012-X] [PMID: 1270556]
[18]
Cohan SL, Pohlmann JL, Mikszewski J, O’Doherty DS. The pharmacokinetics of pyridostigmine. Neurology 1976; 26(6 PT 1): 536-9.
[http://dx.doi.org/10.1212/WNL.26.6.536] [PMID: 945494]
[19]
Davison SC, Hyman N, Prentis RA, Dehghan A, Chan K. The simultaneous monitoring of plasma levels of neostigmine and pyridostigmine in man. Methods Find Exp Clin Pharmacol 1980; 2(2): 77-82.
[PMID: 7339332]
[20]
Sørensen PS, Flachs H, Friis ML, Hvidberg EF, Paulson OB. Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology 1984; 34(8): 1020-4.
[http://dx.doi.org/10.1212/WNL.34.8.1020] [PMID: 6540381]
[21]
Altria KD, Bestford J. Main component assay of pharmaceuticals by capillary electrophoresis: considerations regarding precision, accuracy, and linearity data. J Capillary Electrophor 1996; 3(1): 13-23.
[PMID: 9384760]
[22]
Hadley M, Gilges M, Senior J, Shah A, Camilleri P. Capillary electrophoresis in the pharmaceutical industry: applications in discovery and chemical development. J Chromatogr B Biomed Sci Appl 2000; 745(1): 177-88.
[http://dx.doi.org/10.1016/S0378-4347(00)00153-5] [PMID: 10997713]
[23]
Havel J, Patocka J, Bocaz G. Determination of physostigmine and pyridostigmine in pharmaceutical formulations by capillary electrophoresis. J Capill Electrophor Microchip Technol 2002; 7(5-6): 107-12.
[PMID: 12546159]
[24]
Kornfeld P, Samuels AJ, Wolf RL, Osserman KE. Metabolism of 14C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites. Neurology 1970; 20(7): 634-41.
[http://dx.doi.org/10.1212/WNL.20.7.634] [PMID: 5463535]
[25]
Barber HE, Bourne GR, Calvey TN, Muir KT. The pharmacokinetics of pyridostigmine and 3-hydroxy-N-methylpyridinium in the rat: dose-dependent effects after portal vein administration. Br J Pharmacol 1975; 55(3): 335-41.
[http://dx.doi.org/10.1111/j.1476-5381.1975.tb06936.x] [PMID: 173444]
[26]
Birtley RD, Roberts JB, Thomas BH, Wilson A. Excretion and metabolism of [14C]-pyridostigmine in the rat. Br J Pharmacol Chemother 1966; 26(2): 393-402.
[http://dx.doi.org/10.1111/j.1476-5381.1966.tb01919.x] [PMID: 5912686]
[27]
Ellin RI, Zvirblis P, Wilson MR. Method for isolation and determination of pyridostigmine and metabolites in urine and blood. J Chromatogr A 1982; 228: 235-44.
[http://dx.doi.org/10.1016/S0378-4347(00)80436-3] [PMID: 7076747]
[28]
Abu-Qare AW, Abou-Donia MB. Determination of depleted uranium, pyridostigmine bromide and its metabolite in plasma and urine following combined administration in rats. J Pharm Biomed Anal 2001; 26(2): 281-9.
[http://dx.doi.org/10.1016/S0731-7085(01)00403-4] [PMID: 11470205]
[29]
De Ruyter MG, Cronnelly R, Castagnoli N. Jr Reversed-phase, ion-pair liquid chromatography of quaternary ammonium compounds: determination of pyridostigmine, neostigmine and edrophionium in biological fluids. J Chromatogr A 1980; 183(2): 193-201.
[http://dx.doi.org/10.1016/S0378-4347(00)81693-X] [PMID: 7400278]
[30]
Abu-Qare AW, Abou-Donia MB. Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. J Chromatogr B Biomed Sci Appl 2001; 754(2): 503-9.
[http://dx.doi.org/10.1016/S0378-4347(01)00040-8] [PMID: 11339294]
[31]
Zhao B. Moochala, s.; Lu, J.; Tan, D.; Lai, M. Determination of pyridostigmine bromide and its metabolites in biological samples. J Pharm Pharmaceut Sci Societe Canadienne Des Sci Pharmaceut 2006; 9: 71-81.
[32]
Ali NW, Abdelaleem EA, Naguib IA, Abdallah FF. Development and validation of a stability-indicating high-performance thin-layer chromatographic method for determination of pyridostigmine bromide in the presence of its alkaline-induced degradation product. J Planar Chromatogr Mod TLC 2015; 28(4): 316-22.
[http://dx.doi.org/10.1556/1006.2015.28.4.8]
[33]
Ivanovic D, Medenica M, Jancic B, Knezevic N, Malenovic A, Milic J. Validation of an analytical procedure for simultaneous determination of hydrochlorothiazide, lisinopril, and their impurities. Acta Chromatogr 2007; 18: 143.
[34]
Naguib IA, Abdelrahman MM, El Ghobashy MR, Ali NA. Least-squares regression and spectral residual augmented classical least-squares chemometric models for stability-indicating analysis of agomelatine and its degradation products: a comparative study. J AOAC Int 2016; 99(2): 386-95.
[http://dx.doi.org/10.5740/jaoacint.15-0286] [PMID: 26987554]
[35]
Naguib I A, Darwish H W. Determination of Cefoperazone Sodium in Presence of Related Impurities by Improved Classical Least Squares Chemometric Methods: A Comparative Study 2016.
[http://dx.doi.org/10.1155/2016/7570643]
[36]
Darwish HW, Naguib IA, Darwish IA. Five modified classical least squares based models for stability indicating analysis of cyclobenzaprine HCl with its major degradation products: A comparative study. Spectrochim Acta A Mol Biomol Spectrosc 2018; 204: 598-602.
[http://dx.doi.org/10.1016/j.saa.2018.06.101] [PMID: 29980061]
[37]
Bagtash M, Zolgharnein J. Removal of brilliant green and malachite green from aqueous solution by a viable magnetic polymeric nanocomposite: Simultaneous spectrophotometric determination of 2 dyes by PLS using original and first derivative spectra. J Chemometr 2018; 32(7)e3014
[http://dx.doi.org/10.1002/cem.3014]
[38]
Naguib IA. Improved predictions of nonlinear support vector regression and artificial neural network models via preprocessing of data with orthogonal projection to latent structures: A case study. Bull Fac Pharm Cairo Univ 2017; 55(2): 287-91.
[http://dx.doi.org/10.1016/j.bfopcu.2017.09.002]
[39]
Brereton RG. Multilevel multifactor designs for multivariatecalibration. Analyst (Lond) 1997; 122(12): 1521-9.
[http://dx.doi.org/10.1039/a703654j]
[40]
Olivieri AC, Goicoechea HC, Inón FA. MVC1: an integrated MatLab toolbox for first-order multivariate calibration. Chemom Intell Lab Syst 2004; 73(2): 189-97.
[http://dx.doi.org/10.1016/j.chemolab.2004.03.004]
[41]
Naguib IA, Abdelaleem EA, Draz ME, Zaazaa HE. Linear support vector regression and partial least squares chemometric models for determination of Hydrochlorothiazide and Benazepril hydrochloride in presence of related impurities: a comparative study. Spectrochim Acta A Mol Biomol Spectrosc 2014; 130: 350-6.
[http://dx.doi.org/10.1016/j.saa.2014.04.024] [PMID: 24802720]
[42]
Rahman N, Khan S. Circular Dichroism Spectroscopy: A Facile Approach for Quantitative Analysis of Captopril and Study of Its Degradation. ACS Omega 2019; 4(2): 4252-8.
[http://dx.doi.org/10.1021/acsomega.8b03384]

Rights & Permissions Print Cite
Article Metrics
14
© 2024 Bentham Science Publishers | Privacy Policy